• Explore /
  • Poster
  • / Triple M overlap syndrome (TMOS): Evaluating immune checkpoint inhibitor-related overlap syndrome of myocarditis, myositis and myasthenia gravis using an international pharmacovigilance database.

Triple M overlap syndrome (TMOS): Evaluating immune checkpoint inhibitor-related overlap syndrome of myocarditis, myositis and myasthenia gravis using an international pharmacovigilance database.

Abstract Poster

Authors

Abdul Rafeh Naqash

Abdul Rafeh Naqash

Medical Oncology/TSET Phase 1 Program, Stephenson Cancer Center, University of Oklahoma, Oklahoma City, OK

Abdul Rafeh Naqash , Hassan Mohammed Abushukair , Eman Alghamdi , Mehak Masood Laharwal , Hafsa M Gundroo , Aik-choon Tan , Pauline Funchain , Noha Abdel-Wahab , Elad Sharon , Douglas Buckner Johnson , Amin Nassar , Fawaz F Al-Harbi

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2024 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Developmental Therapeutics—Immunotherapy

Track

Developmental Therapeutics—Immunotherapy

Sub Track

Other Checkpoint Inhibitors (Non-PD1/PDL1, Monotherapy, or Combination)

Citation

J Clin Oncol 42, 2024 (suppl 16; abstr 2643)

DOI

10.1200/JCO.2024.42.16_suppl.2643

Abstract #

2643

Poster Bd #

122

Abstract Disclosures

Similar Posters

First Author: Aanika Balaji

First Author: Taiga KOMATSU

First Author: Michael A. Davies

First Author: Geethika Potluri